GMDA Key Statistics, Chart & Performance
The current stock price of GMDA is 0.0327 USD. In the past month the price decreased by -90.3%. In the past year, price decreased by -95.57%.
GMDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About GMDA
Company Profile
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Company Info
GAMIDA CELL LTD
PO Box 34670
JERUSALEM 95484 IL
CEO: Julian Adams
Employees: 143
Phone: 97226595666
GAMIDA CELL LTD / GMDA FAQ
Can you describe the business of GAMIDA CELL LTD?
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Can you provide the latest stock price for GAMIDA CELL LTD?
The current stock price of GMDA is 0.0327 USD. The price decreased by -18.25% in the last trading session.
What is the dividend status of GAMIDA CELL LTD?
GMDA does not pay a dividend.
What is the ChartMill rating of GAMIDA CELL LTD stock?
GMDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for GMDA stock?
The Revenue of GAMIDA CELL LTD (GMDA) is expected to grow by 808.75% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for GMDA stock?
GAMIDA CELL LTD (GMDA) currently has 143 employees.
GMDA Technical Analysis
GMDA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GMDA. Both the profitability and financial health of GMDA have multiple concerns.
GMDA Financial Highlights
Over the last trailing twelve months GMDA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 49.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.65% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GMDA Forecast & Estimates
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.
For the next year, analysts expect an EPS growth of 9.37% and a revenue growth 808.75% for GMDA